Fresh Wave Of Adalimumab Biosimilars Hits US

Multiple Humira Biosimilar Sponsors Confirm Launch, Offering Details Including Pricing

As launch dates arrive under settlement agreements with Humira originator AbbVie, multiple firms have introduced adalimumab biosimilars in the US, confirming launch and pricing details – with one biosimilar following in the footsteps of Coherus by announcing an 85% discount to the originator.

Multiple rockets and space shuttles launching from Earth into space
As many as eight adalimumab biosimilars will launch in the coming days • Source: Shutterstock

Multi-source US biosimilar competition to Humira (adalimumab) is finally a reality, with multiple sponsors confirming launches of and pricing details for their rivals to the top-selling immunology brand.

After Amgen launched its Amjevita (adalimumab-atto) version at the end of January this year, the market has been preparing for...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin